This is a preview of subscription content, log in via an institution to check access.
Notes
The study was funded by an unrestricted grant from Biogen.
References
Petruzzo M, et al. New diagnostic criteria and the costs for treating multiple sclerosis. 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis : abstr. P396, 10 Oct 2018. Available from: URL: https://onlinelibrary.ectrims-congress.eu/ectrims/2018/ectrims-2018/228241/martina.petruzzo.new.diagnostic.criteria.and.the.costs.for.treating.multiple.html?f=media=3*listing=3*browseby=8
Kobelt G, et al. Real-world outcome in multiple sclerosis estimated from two cost of illness studies and MS clinic data in the Czech Republic. 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis : abstr. P1035, 10 Oct 2018. Available from: URL: https://onlinelibrary.ectrims-congress.eu/ectrims/2018/ectrims-2018/228876/gisela.kobelt.real-world.outcome.in.multiple.sclerosis.estimated.from.two.cost.html?f=media=3*listing=3*browseby=8
Karampampa K, et al. Cost progression regarding healthcare, sickness absence, and disability pension among people newly diagnosed with MS: a register-based longitudinal study in Sweden estimating cost trajectories in four cohorts of incident MS cases over time. 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis : abstr. P397, 10 Oct 2018. Available from: URL: https://onlinelibrary.ectrims-congress.eu/ectrims/2018/ectrims-2018/228242/korinna.karampampa.cost.progression.regarding.healthcare.sickness.absence.and.html?f=media=3*listing=3*browseby=8
Rights and permissions
About this article
Cite this article
Burden of MS: early treatment, better outcomes, lower cost. PharmacoEcon Outcomes News 815, 10 (2018). https://doi.org/10.1007/s40274-018-5391-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5391-3